Allesandro Riva, MD

Articles by Allesandro Riva, MD

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

ByJean-marc A. Nabholtz, MD,Michael Smylie, MD,John R. Mackey, MD,Dick Au, MD,Evelyn Sansregret, MD,Daniel Noel, MD,Alexander H. Paterson, MD,Taher Al-tweigeri, MD,Fernad Delorme, MD,Allesandro Riva, MD

August 1st 1997

Preliminary results from phase I trials suggest that the use of docetaxel (Taxotere) and doxorubicin (Adriamycin) is a well tolerated and highly active combination regimen for

Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer

ByJean-marc A. Nabholtz, MD,B. Thuerlimann, MD,W. R. Bezwoda, MD,D. Melnychuk, MD,L. Deschênes, MD,J. Douma, MD,T. A. Vandenberg, MD,B. Rapoport, MD,R. Rosso, MD,V. Trillet-lenoir, MD,J. Drbal, MD,Matti S. Aapro, MD,M. Alaki, MD,M. Murawsky, MD,Allesandro Riva, MD

August 1st 1997

This nonblinded, multicenter, randomized phase III study compares the median time to progression (primary endpoint), response rate, and quality of life, safety, and survival of

Latest Updated Articles

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer
Published: August 1st 1997 | Updated:
Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer
Published: August 1st 1997 | Updated:

Allesandro Riva, MD

Articles by Allesandro Riva, MD

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma

ADCE-D01 Earns FDA Fast Track Designation in Soft Tissue Sarcoma

Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer

212Pb-Dotamtate Prolongs Responses in Advanced GEP-NETs

KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma